Give now

News

  • October 22, 2020
    LLNL develops first-ever living, 3D-bioprinted aneurysm to test surgical treatments
    Learn more
  • October 19, 2020
    BAF Medical Advisory Board Member, Dr. Brian Hoh Operates on Froggy
    Learn more
  • August 04, 2020
    Stryker’s Neuroform Atlas Stent System granted an expanded indication
    Learn more
  • August 04, 2020
    After a brain aneurysm rupture, can a delayed cerebral ischemia (DCI) be stopped?
    Learn more
  • May 22, 2020
    Neurosurgeons outline reassuring facts and innovative treatment advances
    Learn more
  • February 22, 2020
    Doctors Use Robotics to Treat Brain Aneurysm
    Learn more
  • January 31, 2020
    Why medical polymers are paving the way for more efficient technologies
    Learn more
  • January 23, 2020
    Can Artificial Intelligence be used to Diagnose Brain Aneurysms?
    Learn more
  • January 10, 2020
    2018 Research Grant Recipient developing biomaterial for treatment of aneurysms
    Learn more

In My Area

Support groups
  • AdventHealth Brain Aneurysm Support Group

    Winter Park, FL

    Learn more
  • Baltimore Brain Aneurysm Foundation Support Group

    Lutherville-Timonium, MD

    Learn more
  • Bay Area Aneurysm and Vascular Malformation Support Group

    San Francisco, CA

    Learn more
  • August 04, 2020
  • BAF
  • Technology

Stryker’s Neuroform Atlas Stent System granted an expanded indication

Stryker announced today that it has received U.S. Food and Drug Administration (FDA) approval for an expanded indication of its Neuroform Atlas Stent System, becoming the first and only adjunctive stent approved for use in the posterior (back of the brain) circulation. Aneurysms in the posterior circulation rupture more frequently and are generally more difficult to treat. With the approval of the Neuroform Atlas adjunctive stent for the posterior circulation, long term treatment is more feasible.

Stryker’s Neuroform Atlas® Stent System, which was granted an expanded indication, providing a new option for patients with aneurysms in the back of the brain.

Already approved for use in the anterior circulation, the expanded indication was granted based on robust clinical trial evidence proving the safety and efficacy of the device. The combined patients from both the anterior and posterior cohorts totaled 298 patients, making it the largest study of its kind.

Read full article here

KALAMAZOO, Michigan, USA, Aug. 3, 2020 /PRNewswire



This site uses cookies

Our site uses cookies to personalize features and, via third-parties, to collect metrics on usage so that we can better tailor our site to the needs of our users. You can view our full cookie and privacy policies via the links below. To fully experience our site, please click Accept.